Atezolizumab as first-line therapy for patients with advanced non-small cell lung cancer: A systematic review and meta-analysis on overall survival

被引：0
|
作者：
Marcella, E. [1 ]
Susanto, B. [1 ]
Chen, S. [1 ]
Tandiono, J. [1 ]
Tancherla, A. [1 ]
Heriyanto, R. S. [1 ]
Wijovi, F. [1 ]
Kurniawan, A. [2 ]
机构：
[1] Pelita Harapan Univ, Fac Med, Tangerang, Indonesia
[2] Pelita Harapan Univ, Dept Internal Med, Tangerang, Indonesia
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
112P
引用
收藏
页码：S759 / S759
页数：1
相关论文
共 50 条
  • [1] Atezolizumab Monotherapy or Plus Chemotherapy in First-Line Treatment for Advanced Non-Small Cell Lung Cancer Patients: A Meta-Analysis
    Li, Dan-Ni
    Lu, Wen-Qing
    Yang, Bo-Wen
    Zhang, Ling-Yun
    Jin, Bo
    Wang, Shuo
    Che, Xiao-Fang
    Li, Ce
    Liu, Yun-Peng
    Qu, Xiu-Juan
    [J]. FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [2] Optimal duration of first-line chemotherapy for advanced non-small cell lung cancer: A systematic review with meta-analysis
    da Silveira Nogueira Lima, Joao Paulo
    dos Santos, Lucas Vieira
    Sasse, Emma Chen
    Sasse, Andre Deeke
    [J]. EUROPEAN JOURNAL OF CANCER, 2009, 45 (04) : 601 - 607
  • [3] First-line treatment of patients with advanced or metastatic squamous non-small cell lung cancer: systematic review and network meta-analysis
    Hess, Lisa M.
    DeLozier, Amy M.
    Natanegara, Fanni
    Wang, Xiaofei
    Soldatenkova, Victoria
    Brnabic, Alan
    Able, Stephen L.
    Brown, Jacqueline
    [J]. JOURNAL OF THORACIC DISEASE, 2018, 10 (12) : 6677 - +
  • [4] Atezolizumab in combination with chemotherapy for first-line treatment of advanced non-small cell lung cancer: A systematic review and meta-analysis of randomized controlled trials (RCTs)
    Mogollon-Duffo, F.
    Sultan, A.
    Swarup, S.
    Jahan, N.
    Tun, A. M.
    Htut, T. Win
    Naing, T. W.
    Naing, P. T.
    Myat, Y. Mon
    Hardwicke, F.
    Rehman, S.
    Tijani, L.
    D'Cunha, N.
    Thein, K. Z.
    [J]. ANNALS OF ONCOLOGY, 2019, 30 : 621 - 621
  • [5] Treatment Patterns and Overall Survival Associated with First-Line Systemic Therapy for Patients with Advanced Non-Small Cell Lung Cancer
    Spence, Michele M.
    Hui, Rita L.
    Chang, Jennifer T.
    Schottinger, Joanne E.
    Millares, Mirta
    Rashid, Nazia
    [J]. JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2017, 23 (02): : 159 - 159
  • [6] First-line immunotherapy in non-small cell lung cancer patients with poor performance status: a systematic review and meta-analysis
    Facchinetti, Francesco
    Di Maio, Massimo
    Perrone, Fabiana
    Tiseo, Marcello
    [J]. TRANSLATIONAL LUNG CANCER RESEARCH, 2021, 10 (06) : 2917 - +
  • [7] Anlotinib as treatment for advanced non-small cell lung cancer: A systematic review and meta-analysis on overall survival and progression free survival
    Susanto, B.
    Marcella, E.
    Chen, S.
    Heriyanto, R. S.
    Tandiono, J.
    Wijovi, F.
    Tancherla, A.
    Kurniawan, A.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S792 - S792
  • [8] Immune checkpoint inhibitors as first-line therapy for non-small cell lung cancer: A systematic evaluation and meta-analysis
    Lu, Yu
    Zhang, Xiaoyan
    Ning, Jiyu
    Zhang, Manyan
    [J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2023, 19 (01)
  • [9] Is There a Benefit to Maintenance Therapy After First Line Chemotherapy in Advanced Non-small Cell Lung Cancer - a Systematic Review With Meta-analysis
    Guetz, G. Des
    Uzzan, B.
    Chouahnia, K.
    Nicolas, P.
    Perol, M.
    Morere, J. F.
    [J]. EUROPEAN JOURNAL OF CANCER, 2011, 47 : S593 - S593
  • [10] Taxanes as first-line therapy for advanced non-small cell lung cancer: A systematic review and practice guideline
    Chu, Q
    Vincent, M
    Logan, D
    Mackay, JA
    Evans, WK
    [J]. LUNG CANCER, 2005, 50 (03) : 355 - 374
12345